Kura Oncology, a biopharmaceutical focused on menin inhibitors, highlighted its Q2 2024 financial performance and pipeline breadth during a presentation at Wells Fargo’s 21st Annual Healthcare Conference. The company reported net revenue of $9.1 million, a 57% increase from $5.8 million in Q1 2024, driven by commercial progress in its lead product, KOMZIFTI (ziftomenib).
KOMZIFTI, approved for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML), has secured broad insurance coverage in the U.S., with over 95% of covered lives eligible for step edits or preferred-tier formulary status. As of Q2, the drug had 250 active prescriptions, with 115 new patient starts, reflecting steady commercial momentum. Kura’s gross-to-net discount remains in the 20% to 30% range, consistent with industry benchmarks. The company maintains a robust cash position of $518 million and a debt-to-equity ratio of 0.5, with a current ratio of 4.73.
Kura’s stock has performed well, up 63% over the past year and trading near its 52-week high of $13.90, with a market capitalization of $1.11 billion. Analyst price targets range from $15 to $76, underscoring investor confidence. The company’s peak sales potential for KOMZIFTI in the relapsed/refractory NPM1-mutant AML market is estimated at $350 million to $400 million annually, while its darlifarnib program—targeting kidney cancer and KRAS-positive solid tumors—could generate $5 billion to $6 billion in peak sales.
Beyond KOMZIFTI, Kura is advancing a diverse pipeline. Phase III KOMET-017 trials are enrolling patients globally, testing ziftomenib in combination with intensive chemotherapy and venetoclax/azacitidine. Early data suggest KOMZIFTI may achieve 50% to 60% minimal residual disease (MRD)-negative complete response rates, surpassing standard chemotherapy benchmarks of 44%.
In oncology, divarasib—a menin inhibitor under development for pancreatic ductal adenocarcinoma (PDAC)—showed a 30% response rate and a median overall survival of 13 months. Kura plans a Phase I-A/I-B study combining divarasib with darlifarnib in the first half of 2025, with patient enrollment expected mid-year. Meanwhile, preclinical data for KO-2806, a menin inhibitor for diabetes, were presented at the European Association for the Study of Diabetes (EASD) meeting in late September 2024, demonstrating efficacy in type 1 and type 2 diabetes models.
Kura’s commercial strategy includes a 600 mg daily dosing regimen for KOMZIFTI, with about 40% of patients receiving it in combination therapies, primarily with venetoclax and azacitidine. The average treatment duration for KOMZIFTI is projected at 5.5 to 6 months. The company also secured $180 million in expected milestones from Kyowa Kirin for ziftomenib development.
The company’s forward-looking guidance includes Q4 2024 readouts for Phase I-B data in non-intensive AML settings and KOMET-008 trials, with potential accelerated approval discussions by 2028 based on MRD-negative complete response outcomes from KOMET-017.
